Mutual of America Capital Management LLC Sells 409 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mutual of America Capital Management LLC decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.9% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 13,535 shares of the biopharmaceutical company’s stock after selling 409 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $14,229,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Sachetta LLC increased its position in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares during the period. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. Stephens Consulting LLC bought a new position in Regeneron Pharmaceuticals during the second quarter worth about $26,000. Crewe Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter worth about $28,000. Finally, Lynx Investment Advisory bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $33,000. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on REGN shares. Piper Sandler lowered their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Citigroup started coverage on Regeneron Pharmaceuticals in a research note on Thursday. They set a “neutral” rating and a $895.00 price objective on the stock. Barclays cut their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Friday. They set an “outperform” rating and a $1,150.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,099.55.

Regeneron Pharmaceuticals Trading Down 3.3 %

Shares of REGN stock opened at $756.81 on Friday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $83.17 billion, a P/E ratio of 18.73, a P/E/G ratio of 2.86 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a twelve month low of $753.69 and a twelve month high of $1,211.20. The stock’s fifty day simple moving average is $985.21 and its 200 day simple moving average is $1,033.97.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.